Phenytoin, an anticonvulsant drug, has a narrow therapeutic index and exhibits significant affinity to plasma proteins, mainly albumin. It is mainly metabolized by cytochrome P450 enzymes 2C9, 2C8, and 2C19. The potential for increased phenytoin toxicity may arise when a drug with enzyme-blocking properties are concurrently administered. The co-administration of trimethoprim is reported to decrease phenytoin clearance by 30 %, therefore, monitoring its plasma concentrations is recommended to minimize the risk of its toxicity and optimize its therapeutic efficacy. This study involves development of a novel and simple HPLC method for concurrent measurement of trimethoprim, sulphamethoxazole and phenytoin in plasma samples. The proposed method was optimized using full factorial design to optimize the variable factors affecting chromatographic responses. The separation was performed via isocratic elution on HyperClone C8 column, using a mobile phase consisting of 30: 38.5: 31.5 (v/v/v) of acetonitrile: 3.3 mM heptane-1-sulphonic acid sodium salt: 0.05 M phosphate buffer containing 0.1 % triethylamine at pH 3.7. The mobile phase was delivered at a flow rate of 1 mL/min with UV detection at 210 nm. The method was validated to verify agreement to the criteria set by the International Council for Harmonization (ICH) and Bioanalytical Methods validation. The results showed excellent linearity over the concentration ranges of 0.5–20.0, 1.0–25.0 and 1.0–20.0 µg/mL with detection limits of 0.41, 0.82 and 0.92 µg/mL for trimethoprim, sulphamethoxazole and phenytoin, respectively.The proposed method was extended for the assessment and of the studied drugs in spiked human plasma samples with % recoveries ranging from 92.60 to 105.30 %, indicating bioanalytical applicability. The proposed method can be utilized to study drug-drug interactions for in-patients therapeutic drug monitoring.